Which Peptides Are Being Reclassified in 2026? The Complete List
Written by NorthPeptide Research Team | Reviewed April 23, 2026
Quick summary:
- 14 of 19 peptides are moving from Category 2 (restricted) → Category 1 (eligible for compounding)
- Category 1 = available through licensed compounding pharmacies with a prescription
- This is NOT the same as FDA drug approval
- FDA advisory committee confirmed for late July 2026 (first 7 peptides) and February 2027 (5 more)
- 5 peptides are expected to remain restricted
If you've searched "are peptides legal again" or "which peptides are coming back" in the last two months, you're not alone. Since HHS Secretary RFK Jr. announced on Joe Rogan that 14 peptides would be moving out of Category 2, the number one question in the peptide space has been simple: which ones?
This article answers that question. Every peptide on the list, what each one is known for, which ones are on the confirmed July 2026 FDA panel agenda, and what reclassification actually means for how you access them.
What Does Reclassification Actually Mean?
Before we get into the list, let's clear up what "reclassification" actually means — because most of the headlines get this wrong.
Category 2 → Category 1 is not "legalization." These peptides were never illegal to possess or research. What Category 2 did was shut off one specific pathway: compounding pharmacies couldn't prepare them for patients anymore. No prescription, no pharmacy, no regulated access.
Category 1 means:
- A doctor can write you a prescription
- A licensed 503A compounding pharmacy can prepare it
- Quality controls, testing, and pharmaceutical standards apply
- It's regulated, tracked, and legitimate
Category 1 does NOT mean:
- Over-the-counter sales
- FDA-approved drugs (that's a completely different process)
- That any company can sell peptides without regulation
Think of it this way: Category 2 locked the front door. Category 1 opens it again. But you still need a key (a prescription) and the door is still in a regulated building (a licensed pharmacy).
For the full regulatory backstory — including the SAFE Act and how the 2023 crackdown played out — see our detailed breakdown of the RFK Jr. announcement and its regulatory context.
The 14 Peptides Being Reclassified
Here's every peptide expected to move from Category 2 to Category 1, grouped by what they're primarily known for.
Recovery & Healing
BPC-157 — The Recovery Peptide
BPC-157 is probably the most well-known peptide on this list. It's the one people reach for when they're dealing with tendon injuries, joint pain, or gut issues. Derived from a protein found in human gastric juice, BPC-157 has been studied extensively for its role in tissue repair — tendons, ligaments, muscle, and the GI tract.
If you've spent any time in fitness or biohacking communities, you've heard of BPC-157. It's the peptide that people credit with getting them back in the gym after injuries that weren't healing on their own.
FDA July panel: ✓ On the agenda
Status: Currently Category 2 — expected Category 1
TB-500 (Thymosin Beta-4) — Tissue Repair & Flexibility
TB-500 is BPC-157's frequent partner. Where BPC-157 is known for localized healing, TB-500 has a reputation for systemic tissue repair — it works throughout the body. Athletes and people with chronic injuries use it for flexibility, recovery from muscle tears, and reducing inflammation.
TB-500 is also one of the peptides most commonly stacked with BPC-157, and the combination has become something of a standard protocol in the recovery community.
FDA July panel: ✓ On the agenda
Status: Currently Category 2 — expected Category 1
GHK-Cu (Copper Peptide) — Wound Healing & Skin Remodeling
GHK-Cu is the peptide that sits at the intersection of healing and anti-aging. It's a naturally occurring peptide that your body produces less of as you age. Research shows it promotes wound healing, stimulates collagen production, and has anti-inflammatory properties. It's popular both in injectable form and as a topical for skin rejuvenation.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
Cognitive & Mood
Semax — Focus & Cognitive Performance
Semax has built a following among people who want sharper focus and better cognitive performance without stimulants. Originally developed in Russia as a treatment for stroke and cognitive disorders, Semax works by increasing BDNF (brain-derived neurotrophic factor) — essentially telling your brain to grow and strengthen neural connections.
It's the peptide people turn to when they want the benefits of a nootropic without the crash, the jitters, or the tolerance buildup that comes with stimulants.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
Selank — Stress, Anxiety & Mood
Selank is Semax's calmer sibling. Where Semax is about sharpening cognition, Selank is about reducing anxiety and stabilizing mood. It works through GABA modulation — the same system that anti-anxiety medications target, but without the sedation or dependency risk that comes with benzodiazepines.
People who use Selank describe it as "taking the edge off" without feeling medicated. It's particularly popular among people dealing with chronic stress or anxiety who don't want pharmaceutical side effects.
FDA July panel: TBC
Status: Removed from Category 2 in September 2024 — expected formal Category 1
Emideltide (DSIP) — Sleep & Stress Response
DSIP — Delta Sleep-Inducing Peptide — does roughly what the name suggests. It's studied for its role in regulating sleep architecture, particularly deep sleep (delta wave sleep). Beyond sleep, DSIP research has explored its effects on stress response and pain tolerance.
For people who've tried everything for sleep — melatonin, magnesium, sleep hygiene — DSIP represents a different approach: working with your body's own sleep signaling rather than sedating it.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
Metabolic & Body Composition
AOD-9604 — Fat Metabolism
AOD-9604 is the peptide people reach for when the goal is body composition. It's a modified fragment of human growth hormone (specifically the fat-burning portion) that's been studied for its ability to stimulate lipolysis — the breakdown of fat — without the side effects associated with full HGH.
It's particularly popular among people who want the metabolic benefits of growth hormone without affecting blood sugar or promoting tissue growth in places you don't want it.
FDA July panel: TBC
Status: Removed from Category 2 in September 2024 — expected formal Category 1
MOTS-C — Metabolic Function & Exercise Performance
MOTS-C is a mitochondrial-derived peptide — meaning your own mitochondria produce it. It's been called an "exercise mimetic" because research shows it activates many of the same metabolic pathways that exercise does: improved insulin sensitivity, better fat oxidation, and enhanced cellular energy production.
For people interested in metabolic health, longevity, or getting more out of their training, MOTS-C is one of the most interesting peptides on this list.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
Immune Function
Thymosin Alpha-1 — Immune Support & Modulation
Thymosin Alpha-1 is the immune system's peptide. Produced naturally by the thymus gland, it plays a central role in immune function — specifically in how your body activates T-cells and natural killer cells to fight infections and abnormal cells.
It's been used clinically in over 30 countries (marketed as Zadaxin) for hepatitis B, hepatitis C, and as an immune adjuvant. Practitioners in integrative medicine have used it for years for patients with compromised or underperforming immune systems.
FDA July panel: TBC
Status: Removed from Category 2 in September 2024 — expected formal Category 1
KPV — Inflammation, Gut Health & Skin
KPV is a tripeptide (just three amino acids) derived from alpha-MSH, and it punches well above its weight. Research focuses on its anti-inflammatory properties — particularly for gut inflammation (IBD, colitis) and inflammatory skin conditions.
It's become popular in the biohacking community for people dealing with chronic gut issues who haven't found relief through conventional approaches.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
Growth Hormone & Hormonal
CJC-1295 — Growth Hormone Releasing Hormone
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). It tells your pituitary gland to produce more growth hormone — not a flood of synthetic HGH, but your own natural production turned up. Available in two forms: with DAC (longer half-life, sustained release) and without DAC (shorter pulses, more natural rhythm).
It's most commonly paired with Ipamorelin as a synergistic stack — one stimulates GH release, the other amplifies it.
FDA July panel: TBC
Status: Removed from Category 2 in September 2024 — expected formal Category 1
Ipamorelin — Clean Growth Hormone Release
Ipamorelin is considered one of the "cleanest" growth hormone releasing peptides available. Unlike older GHRPs (like GHRP-6, which famously makes you ravenously hungry), Ipamorelin selectively stimulates growth hormone release without spiking cortisol, prolactin, or appetite.
That selectivity is why it's become one of the most popular peptides in anti-aging and performance protocols — you get the GH benefits without the baggage.
FDA July panel: TBC
Status: Removed from Category 2 in September 2024 — expected formal Category 1
Kisspeptin-10 — Reproductive Health & Fertility
Kisspeptin-10 is the master regulator of the HPG axis — the hormonal cascade that controls testosterone, estrogen, and reproductive function. It's been studied for fertility (both male and female), for restarting natural testosterone production after suppression, and as a diagnostic tool in reproductive endocrinology.
It's niche compared to BPC-157 or TB-500, but for people dealing with hormonal issues or fertility challenges, it's one of the most important peptides on this list.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
Longevity & Anti-Aging
Epitalon — Telomerase Activation & Aging
Epitalon is the longevity peptide. It's a synthetic version of epithalamin, a peptide produced by the pineal gland. The key research finding: Epitalon activates telomerase, the enzyme that rebuilds telomeres — the protective caps on your chromosomes that shorten with age.
Shorter telomeres are associated with aging and age-related diseases. Epitalon's ability to lengthen them (demonstrated in human cell studies) is why it's become a centerpiece of anti-aging peptide protocols.
FDA July panel: TBC
Status: Currently Category 2 — expected Category 1
The 5 Peptides That Remain Restricted
Not every peptide from the original 19 is coming back. Approximately five are expected to stay in Category 2 or under continued restriction:
| Peptide | Why It's Staying Restricted |
|---|---|
| Melanotan II | Flagged by multiple international regulatory bodies for safety concerns. Side effect profile includes nausea, facial flushing, and more serious cardiovascular concerns at higher doses. |
| Dihexa Acetate | Extremely potent cognitive peptide with very limited human safety data. Its potency (active at picomolar concentrations) means the margin for error is small. |
| PEG-MGF | PEGylated growth factor fragment. The combination of growth-promoting activity and PEGylation raises specific safety questions the FDA hasn't resolved. |
| Cathelicidin LL-37 | Powerful antimicrobial peptide, but its immune-activating properties create a complex safety profile that requires more evaluation. |
| Ibutamoren (MK-677) | Technically a growth hormone secretagogue, not a peptide. Has been the subject of adverse event reports and carries concerns about prolonged GH elevation. |
The specific reasons for keeping these five restricted haven't been detailed publicly. But the pattern is clear: these are either compounds with documented adverse events (Melanotan II, MK-677), limited human safety data (Dihexa), or complex mechanisms that require more study (LL-37, PEG-MGF).
The Timeline — When Does This Actually Happen?
| Date | What Happens | Why It Matters |
|---|---|---|
| September 2023 | FDA places all 19 peptides on Category 2 | Compounding access shut off for all 19 |
| September 2024 | 5 peptides removed from Category 2 | AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank — restrictions lifted |
| February 27, 2026 | RFK Jr. announces on Joe Rogan | 14 peptides to move to Category 1 — political will confirmed |
| Late July 2026 | FDA advisory committee (confirmed) | First 7 peptides evaluated — including BPC-157 and TB-500 |
| By February 2027 | Second FDA advisory panel | 5 additional peptides evaluated |
| TBD | Formal Category list updated | The date that actually changes the legal framework |
The important nuance: The advisory committee makes a recommendation. The FDA then decides whether to act on it. Historically, the FDA follows advisory committee recommendations the vast majority of the time — but the formal reclassification requires the FDA to publish an updated Category list. Until that happens, the current restrictions technically remain in effect.
What This Means If You're Already Using Peptides
If you've been using peptides for recovery, performance, or health — here's the bottom line:
You're not fringe. You're early.
The compounds people have been using for tendon healing, cognitive performance, immune support, and metabolic health aren't going away — they're getting legitimized. The reclassification means access through regulated, quality-controlled channels. It means your doctor can be part of the conversation. It means the substances you use will be held to pharmaceutical compounding standards.
What changes:
- Sourcing — compounding pharmacies with quality controls become the standard channel
- Prescriptions — a doctor writes it, a pharmacy fills it
- Quality — compounding standards, testing requirements, regulatory oversight
- Potentially cost — compounding pharmacy pricing may differ from research supplier pricing (in both directions)
What doesn't change:
- The research — the studies on BPC-157, TB-500, Semax, and others aren't affected by regulatory categories
- The community — the knowledge, protocols, and experience people have built
- The reasons people started using peptides in the first place
For a deeper look at what the reclassification means for the industry, quality standards, and the people who've been in the peptide space for years, read our editorial: What Peptide Reclassification Means for the Future of the Industry.
Frequently Asked Questions
Are peptides legal now?
Peptides were never "illegal" in the way most people think. What happened in 2023 was that the FDA restricted specific peptides from being compounded by pharmacies (Category 2 designation). The reclassification to Category 1 would restore compounding pharmacy access — meaning a doctor can prescribe them and a licensed pharmacy can prepare them. Research peptides have remained available throughout.
Can I buy peptides online?
Research peptides are available from research chemical suppliers like NorthPeptide. These are sold for laboratory and research purposes. Compounded peptides (once reclassified to Category 1) will be available through licensed compounding pharmacies with a valid prescription. These are two different supply chains with different regulatory frameworks.
What's the difference between compounding pharmacy peptides and research peptides?
Compounding pharmacies operate under Section 503A of the FD&C Act — they prepare patient-specific medications under a doctor's prescription with pharmaceutical quality controls. Research peptide suppliers sell reference materials for laboratory use. Both can provide high-purity peptides, but the regulatory framework, intended use, and access pathway are different.
When will the FDA publish the final reclassification list?
The FDA advisory committee is confirmed for late July 2026 (first 7 peptides) and February 2027 (5 additional). After the advisory committee makes its recommendation, the FDA must publish a formal update to the Category list. The exact publication date has not been announced, but it typically follows within weeks to months of the advisory committee meeting.
Related Articles
- RFK Jr on Joe Rogan: 14 Peptides Moving Out of Category 2 — FDA Panel Confirmed July 2026
- The SAFE Act and Peptide Research: What You Need to Know in 2026
- Peptide Sciences Shutdown 2026: What Happened and Where to Find Research Peptides
- What Peptide Reclassification Means for the Future of the Industry
Products mentioned in this article:
Summary of Key Research References
| Study | Year | Type | Focus | Reference |
|---|---|---|---|---|
| Seiwerth et al. | 2018 | Review | BPC-157 — stable gastric pentadecapeptide: novel therapy for gastrointestinal tract | PMC6271067 |
| Aber et al. | 2021 | Review | Thymosin Beta-4 (TB-500) — role in tissue repair and regeneration | PMC7885421 |
| Tuthill et al. | 2020 | Review | Thymosin Alpha-1 — clinical applications in immunotherapy | PMC7260509 |
| Pickart et al. | 2015 | Review | GHK-Cu — regenerative and protective actions on multiple body systems | PMC4508379 |
| Lee et al. | 2015 | Original | MOTS-c — a novel mitochondrial-derived peptide regulating metabolism | PMC4350682 |
| Obesity Medicine Association | 2024 | Position Statement | Compounded peptides — regulatory framework and clinical considerations | PMC11369382 |
| Khavinson et al. | 2003 | Original | Epithalon peptide — telomerase activation in human somatic cells | PMC3738205 |
Written by NorthPeptide Research Team
Ready to explore research-grade peptides?
Disclaimer: This article is for informational and educational purposes only. All peptides mentioned are intended for laboratory and research use only. Not for human consumption. NorthPeptide products are research chemicals and are not approved for medical use. Always consult applicable laws and regulations in your jurisdiction.